Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Shanghai Henlius Biotech, Inc. ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.46%
- Poor long term growth as Operating profit has grown by an annual rate 23.63% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
With ROE of 27.74%, it has a Very Expensive valuation with a 3.97 Price to Book Value
- Over the past year, while the stock has generated a return of 191.24%, its profits have risen by 47.8% ; the PEG ratio of the company is 0.3
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality key factors
Factor
Value
Sales Growth (5y)
56.45%
EBIT Growth (5y)
23.63%
EBIT to Interest (avg)
-4.03
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.91
Sales to Capital Employed (avg)
0.66
Tax Ratio
3.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.46%
ROE (avg)
10.54%
Valuation Key Factors 
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
3.97
EV to EBIT
16.66
EV to EBITDA
11.63
EV to Capital Employed
2.56
EV to Sales
2.52
PEG Ratio
0.30
Dividend Yield
NA
ROCE (Latest)
15.34%
ROE (Latest)
27.74%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Technical Movement
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Shanghai Henlius Biotech, Inc.
Operating Profit
Highest at HKD 672.78 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (HKD MM)
Pre-Tax Profit
Highest at HKD 488.34 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (HKD MM)
Net Profit
Highest at HKD 470.99 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (HKD MM)
Debt-Equity Ratio
Lowest at 95.41 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales
Highest at HKD 3,230.94 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (HKD MM)
EPS
Highest at HKD 0.87
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (HKD)
Inventory Turnover Ratio
Highest at 2.15%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -4.28% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at HKD 219.34 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (HKD MM)
Depreciation
At HKD 219.34 MM has Grown at 17.27%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (HKD MM)
Here's what is not working for Shanghai Henlius Biotech, Inc.
Debtors Turnover Ratio
Lowest at 6.27%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Non Operating Income
Highest at HKD 0.2 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income






